Distribution agreement and capital increase: AVO is focused on delivering a more affordable, novel, proton-based radiotherapy system, based on technology originally developed at the world-renowned CERN. Major milestones have been achieved in 2017 and the company remains on track with its development plan to deliver and install the first LIGHT system in 2019. Confidence has been enhanced greatly with integration of the first three structures, overcoming technical challenges of accelerating the proton beam. Announcement of a distribution agreement for China, and a sizeable capital increase should resolve the market’s concerns about long-term funding of this important project.
Please click here for the full report:
To contact us:
Hardman & Co
35 New Broad Street
Dr Martin Hall firstname.lastname@example.org
Dr Dorothea Hill email@example.com
Dr Gregoire Pave firstname.lastname@example.org
Telephone: +44 20 7194 7622
Follow us on Twitter @HardmanandCo
About Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors’ understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies’ profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.
Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.
Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.